Eli Lilly has crossed $20 billion in acquisitions in 2026 — a company record.1 Three deals define the run: Kelonia Therapeutics at $7 billion, Centessa Pharmaceuticals at $7.8 billion, and three vaccine developers acquired for a combined $3.8 billion.1
The pace is not opportunistic. It reflects a structural bet on how AI is changing drug development economics.
AI-driven discovery platforms are reducing pre-clinical timelines.1 That compression raises the strategic value of early-stage pipeline assets. For large pharma, it shifts the build-versus-buy calculus — acquired biotechs with AI-native platforms now carry more optionality than comparable companies a decade ago.
Lilly's history sharpens the urgency. When the Prozac patent expired, the company endured a decade of revenue pressure.1 The current acquisition drive reads as a preemptive rebuild — deploying capital before a similar cliff materializes.
Each deal targets a different exposure. Centessa, the largest at $7.8 billion, brings a diversified platform across multiple therapeutic areas.1 Kelonia adds targeted oncology assets at $7 billion.1 The three vaccine acquisitions, totaling $3.8 billion, expand Lilly's immunology and infectious disease footprint.1
The deeper question is what happens to internal R&D. If Lilly's R&D spending as a share of revenue falls while deal volume grows, it signals a structural pivot — outsourcing discovery risk to earlier-stage companies, then acquiring validated targets. That model only works if AI tools reduce the cost of evaluating and integrating acquired pipelines at scale.
Peers with lower acquisition activity face a direct comparison. Pipeline growth rates, time-to-IND submissions, and Phase II success ratios will eventually reveal whether Lilly's capital deployment outperforms conventional internal research investment.
The $20 billion figure is a bet, not a proven strategy. Early-stage acquisitions carry pipeline attrition, integration complexity, and execution risk. But in a market where AI is compressing discovery timelines, the cost of waiting may now exceed the cost of buying early.
